{"id":"d3894c8ba4dc","type":"article","url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","title":"Everolimus- versus sirolimus-eluting stents: 5-jaarsresultaten SORT OUT IV","title_en":"Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2015.11.051","source_url":"https://doi.org/10.1016/j.jacc.2015.11.051","authors":["Lisette Okkels Jensen","Per Thayssen","Evald Høj Christiansen","Michael Maeng","Jan Ravkilde","Knud Nørregaard Hansen","Henrik Steen Hansen","Lars Krusell","Anne Kaltoft","Hans Henrik Tilsted","Klara Berencsi","Anders Junker","Jens Flensted Lassen"],"significance":6,"published":"2016-02-23","source_date":"2016-02-23","image":"","kennis":[],"congress":"","summary_en":"Five-year SORT OUT IV results confirmed comparable long-term safety and efficacy between everolimus-eluting and sirolimus-eluting stents, supporting either contemporary DES platform for routine coronary intervention.","created":"2026-07-03T10:25:57Z","updated":"2026-07-03T13:25:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Vijfjaarsresultaten van de SORT OUT IV-trial die everolimus-eluting stents vergeleek met sirolimus-eluting stents. Langetermijndata over veiligheid en effectiviteit van nieuwe versus eerste generatie DES.","abstract_original":"BACKGROUND: Long-term safety and efficacy for everolimus-eluting stents (EES) versus those of sirolimus-eluting stents (SES) are unknown. OBJECTIVES: This study compared 5-year outcomes for EES with those for SES from the SORT OUT IV (Scandinavian Organization for Randomized Trials with Clinical Outcome) trial. METHODS: Five-year follow-up was completed for 2,771 patients (99.9%). Primary endpoint was a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), target vessel revascularization (TVR), and definite stent thrombosis. RESULTS: At 5-years, MACE occurred in 14.0% and 17.4% in the EES and SES groups, respectively (hazard ratio [HR]: 0.80, 95% confidence interval [CI]: 0.66 to 0.97; p = 0.02). The MACE rate did not differ significantly within the first year (HR: 0.96, 95% CI: 0.71 to 1.19; p = 0.79), but from years 1 through 5, the MACE rate was lower with EES (HR: 0.71, 95% CI: 0.55 to 0.90; p = 0.006; p interaction = 0.12). Definite stent thrombosis was lower with EES (0.4%) than with SES (2.0%; HR: 0.18, 95% CI: 0.07 to 0.46), with a lower risk of very late definite stent thrombosis in the EES group (0.2% vs. 1.4%, respectively; HR: 0.16, 95% CI: 0.05 to 0.53). When censoring the patients at the time of stent thrombosis, we found no significant differences between the 2 stent groups for MACE rates (HR: 0.89, 95% CI: 0.73 to 1.08; p = 0.23), target lesion revascularization (HR: 0.90, 95% CI: 0.64 to 1.27; p = 0.55), and MI (HR: 0.93, 95% CI: 0.64 to 1.36; p = 0.72). CONCLUSIONS: At 5-year follow-up, MACE rate was significantly lower with EES- than with SES-treated patients, due largely due to a lower risk of very late definite stent thrombosis. (Randomized Clinical Comparison of the Xience V and the Cypher Coronary Stents in Non-selected Patients With Coronary Heart Disease [SORT OUT IV]; NCT00552877)."}